Baxdrostat is named as an intervention in 2 current clinical trials in our Canada, UK, USA, India, China, Germany, France, Spain, Italy, Japan, Taiwan and Australia registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is AstraZeneca (1). The most-studied condition is Primary Hyperaldosteronism. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Baxdrostat was first approved in the US on 15 May 2026.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793 · ClinicalTrials.gov ↗ · Primary Hyperaldosteronism
|
Phase 3 | Recruiting | AstraZeneca | UK, USA, India, China, Germany, France, Spain, Italy, Canada, Japan, Taiwan, Australia |
|
Baxdrostat and Ventricular Remodeling
NCT07655362 · ClinicalTrials.gov ↗ · Cardiac Remodeling
|
Phase 3 | Not yet open | Subodh Verma | Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Baxdrostat. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase IIb, Randomised, Multicentre, Double-Blind Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Baxdrostat on Albuminuria in Participants with Chronic Kidney Disease and High Blood Pressure
2025-522407-23-00 · CTIS ↗ · Cardiovascular Diseases
|
Phase 2 | Ongoing | AstraZeneca AB | Spain, Bulgaria |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Subodh Verma | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our Canada, UK, USA, India, China, Germany, France, Spain, Italy, Japan, Taiwan and Australia registers name Baxdrostat as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Canada, 1 with sites in UK, 1 with sites in USA, 1 with sites in India, 1 with sites in China, 1 with sites in Germany, 1 with sites in France, 1 with sites in Spain, 1 with sites in Italy, 1 with sites in Japan, 1 with sites in Taiwan and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
AstraZeneca (1) and Subodh Verma (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Baxdrostat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Baxdrostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Baxdrostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.